Abstract：
In the past 3 decades, metabolic-associated fatty liver disease (MAFLD) has emerged as a widespread liver condition, with its global prevalence on the rise. It ranks as a leading contributor to hepatocellular carcinoma (HCC) and necessitates liver transplantation. Under the multiple parallel hits model, the pathogenesis of MAFLD stems from various liver stressors, notably nutrient overload and sedentary lifestyles. While medical management for MAFLD is well-established, encompassing non-pharmaceutical and pharmaceutical interventions, determining the most effective pharmaceutical therapy has remained elusive. This review discusses diabetic medications for MAFLD treatment, emphasizing recent studies and emerging drugs while reviewing other nondiabetic agents. Emerging evidence suggests that combination therapies hold promise for resolving MAFLD and metabolic steatohepatitis (MASH) while managing side effects. Ongoing trials play a pivotal role in elucidating the effects of mono, dual, and triple receptor agonists in individuals with MASH. With the rising burden of MAFLD/MASH and its severe consequences, the need for effective treatments is more pressing than ever. This review provides a comprehensive overview of the current landscape of pharmaceutical interventions for MAFLD and MASH, shedding light on the potential of newer drugs especially diabetic medications and the importance of ongoing research in this field.
摘要：
在过去的30年里,代谢相关脂肪性肝病（MAFLD）已成为一种广泛的肝脏疾病，随着其全球流行率的上升。它是肝细胞癌（HCC）的主要贡献者，需要肝移植。在多个并行命中模型下，MAFLD的发病机制源于各种肝脏应激源，特别是营养超载和久坐不动的生活方式。虽然MAFLD的医疗管理已经成熟，包括非药物和药物干预，确定最有效的药物治疗仍然难以捉摸。这篇综述讨论了用于MAFLD治疗的糖尿病药物，在回顾其他非糖尿病药物的同时，强调最近的研究和新兴药物。新出现的证据表明，联合疗法有望解决MAFLD和代谢性脂肪性肝炎（MASH），同时管理副作用。正在进行的试验在阐明单核细胞增多症的影响中起着关键作用，双重,和MASH患者的三重受体激动剂。随着MAFLD/MASH负担的增加及其严重后果，对有效治疗的需求比以往任何时候都更加紧迫。这篇综述全面概述了MAFLD和MASH的药物干预措施的现状，揭示了新药，尤其是糖尿病药物的潜力，以及该领域正在进行的研究的重要性。
